SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D illustration of many pawns attracted by a red one. Concept of aura of attraction and charismatic person.3D rendering on black background.
Rare diseases
Dyne Primed for Suitors Amid Novartis’ $12B Avidity Acquisition
The takeover of its competitor, announced Sunday, could also bring some attention to Dyne Therapeutics, which has a similar RNA-based pipeline in rare muscle diseases.
October 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Bayer's factory and office in Berlin
Approvals
Bayer Gets FDA Nod for Novel Drug to Treat Hot Flashes
Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.
October 27, 2025
 · 
1 min read
 · 
Tristan Manalac
Sponsored
Best Pharmaceutical Label Manufacturers: Reviews and Comparisons
Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.
October 27, 2025
 · 
6 min read
Daniel and Kaori Barvin sharing their story of lay leadership at the Seattle Jewish Federation's Fall Fundraiser.
ALS
Coya Exec Daniel Barvin Is on a Mission To End Genetic ALS and FTD
The BioSpace 40 Under 40 winner opens up about his very personal career transformation from wealth management to biotech—and what it’s like to develop a drug for amyotrophic lateral sclerosis and frontotemporal dementia as a potential patient himself.
October 27, 2025
 · 
5 min read
 · 
Heather McKenzie
The journey forward, the successful forward progress and advancement of a business or profession, the achievement of success or the attainment of a goal, a group of businessmen running forward with arrows in their hands
Huntington’s disease
4 Huntington’s Therapies Chasing UniQure
Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at four more candidates on the near horizon.
October 27, 2025
 · 
6 min read
 · 
Heather McKenzie
Brain , concept idea art of thinking, surreal portrait painting, conceptual artwork, 3d illustration
Huntington’s disease
UniQure’s Huntington’s Breakthrough Brings Hope to Patients but Experts Urge Caution
Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only disappointment in recent years—but one expert worries that communication of the results is creating “false expectations.”
October 27, 2025
 · 
6 min read
 · 
Heather McKenzie
Marburg, Germany - July 6, 2013: Marburg Office of Swiss multinational company Novartis AG
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
The deal, announced early Sunday afternoon, will see Novartis gain access to Avidity’s neuroscience assets, while the San Diego biotech spins out a new company to shepherd its early-stage precision cardiology programs.
October 26, 2025
 · 
2 min read
 · 
Heather McKenzie
Cambridge, USA - 26 July 2024. View of leading global biotechnology company Biogen office exterior banner logo sign, Biotech industry
Immunology and inflammation
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule
The $70 million upfront deal adds to a portfolio of drugs Biogen has been growing in various immunological conditions since 2024.
October 24, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Eli Lilly's headquarters in Indianapolis
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet age-related macular degeneration. Eli Lilly made another foray into genetic medicine in June, picking up Verve Therapeutics for up to $1.3 billion.
October 24, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS